Definiens

About:

Definiens provides image analysis and data mining solutions for quantitative digital pathology in the healthcare industries.

Website: http://www.definiens.com

Twitter/X: DefiniensLife

Top Investors: Wellington Partners, Ventech, Cipio Partners, TVM Capital, Gilde Healthcare

Description:

Definiens is the provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived from other sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and supports better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives. Definiens is headquartered in Munich, Germany, and has offices throughout the United States.

Total Funding Amount:

25M EUR

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

Munich, Bayern, Germany

Founded Date:

1994-01-01

Contact Email:

support(AT)definiens.com

Founders:

Gerd Binnig

Number of Employees:

51-100

Last Funding Date:

2014-06-23

IPO Status:

Private

Industries:

© 2025 bioDAO.ai